{"id":15182,"date":"2026-01-16T17:43:27","date_gmt":"2026-01-16T17:43:27","guid":{"rendered":"https:\/\/inbudgetalerts.com\/?p=15182"},"modified":"2026-01-16T17:43:27","modified_gmt":"2026-01-16T17:43:27","slug":"ocugen-why-i-dont-read-too-much-into-the-selloff-on-phase-2-ga-data-nasdaqocgn","status":"publish","type":"post","link":"https:\/\/inbudgetalerts.com\/?p=15182","title":{"rendered":"Ocugen: Why I Don&#8217;t Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN)"},"content":{"rendered":"<div data-test-id=\"author-root\">\n<p class=\"mb-12 text-medium-2-r text-share-text-3\">This article was written by<\/p>\n<div class=\"relative mb-12 flex justify-between\">\n<div class=\"flex\">\n<div class=\"flex shrink-0 items-center justify-center relative size-36 rounded-full\" data-test-id=\"user-pic-wrapper\"><\/div>\n<\/div>\n<p><button data-state-text=\"Following\" aria-label=\"Follow Edmund Ingham\" class=\"ihjjQ py-8 px-18 o7ZP8 ml-8 mt-0 shrink-0 self-baseline text-small-b relative inline-flex cursor-pointer select-none items-center whitespace-nowrap break-words transition-colors hover:no-underline motion-reduce:transition-none border-black bg-black text-white hover:bg-black-70 disabled:border-transparent disabled:bg-black-20 dark:border-black-10 dark:bg-black-10 dark:text-black dark:hover:border-black-30 dark:hover:bg-black-30 dark:disabled:bg-black-30 w-auto min-h-28 justify-center border px-12 py-1 text-medium-r rounded-6\" data-test-id=\"follow-button\" type=\"button\"><span class=\"\"><span aria-hidden=\"true\" class=\"wMAFB relative flex justify-center\" data-state-placeholder=\"Following\"><span class=\"absolute\">Follow<\/span><\/span><\/span><\/button><\/p>\n<\/div>\n<div class=\"text-medium-2-r\">\n<div class=\"relative\">\n<div class=\"relative overflow-hidden\" style=\"max-height:100%\">\n<div>\n<p>Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. <\/p>\n<p>The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div data-test-id=\"content-container\">\n<p id=\"a-disclosure\"><b>Analyst\u2019s Disclosure:<\/b><span>I\/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.<\/span><span id=\"top-business-disclosure\"> I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. <\/span><\/p>\n<p id=\"a-disclosure-more\"><strong>Seeking Alpha&#8217;s Disclosure:<\/strong> Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.<\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/seekingalpha.com\/article\/4860533-ocugen-why-i-dont-read-too-much-into-selloff-on-phase-2-ga-data?source=feed_all_articles\" target=\"_blank\" rel=\"noopener\" rel=\"nofollow\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This article was written by Follow Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over&#8230;<\/p>\n","protected":false},"author":1,"featured_media":15183,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":{"0":"post-15182","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-news"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ocugen: Why I Don&#039;t Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN) | InBudgetAlerts<\/title>\n<meta name=\"description\" content=\"This article was written byFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/inbudgetalerts.com\/?p=15182\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocugen: Why I Don&#039;t Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN) | InBudgetAlerts\" \/>\n<meta property=\"og:description\" content=\"This article was written byFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put\" \/>\n<meta property=\"og:url\" content=\"https:\/\/inbudgetalerts.com\/?p=15182\" \/>\n<meta property=\"og:site_name\" content=\"InBudgetAlerts\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-16T17:43:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/inbudgetalerts.com\/wp-content\/uploads\/2026\/01\/image_1306234498.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1025\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Press Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Press Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/inbudgetalerts.com\/?p=15182#article\",\"isPartOf\":{\"@id\":\"https:\/\/inbudgetalerts.com\/?p=15182\"},\"author\":{\"name\":\"Press Room\",\"@id\":\"https:\/\/inbudgetalerts.com\/#\/schema\/person\/5fadb0c23fa3bfd2762b1a5dcce46da3\"},\"headline\":\"Ocugen: Why I Don&#8217;t Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN)\",\"datePublished\":\"2026-01-16T17:43:27+00:00\",\"dateModified\":\"2026-01-16T17:43:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/inbudgetalerts.com\/?p=15182\"},\"wordCount\":268,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/inbudgetalerts.com\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/inbudgetalerts.com\/?p=15182#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/inbudgetalerts.com\/?p=15182\",\"url\":\"https:\/\/inbudgetalerts.com\/?p=15182\",\"name\":\"Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN) | InBudgetAlerts\",\"isPartOf\":{\"@id\":\"https:\/\/inbudgetalerts.com\/#website\"},\"datePublished\":\"2026-01-16T17:43:27+00:00\",\"dateModified\":\"2026-01-16T17:43:27+00:00\",\"description\":\"This article was written byFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put\",\"breadcrumb\":{\"@id\":\"https:\/\/inbudgetalerts.com\/?p=15182#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/inbudgetalerts.com\/?p=15182\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/inbudgetalerts.com\/?p=15182#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/inbudgetalerts.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocugen: Why I Don&#8217;t Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/inbudgetalerts.com\/#website\",\"url\":\"https:\/\/inbudgetalerts.com\/\",\"name\":\"Fintech Advance\",\"description\":\"Latest Finance and Tech News and Updates\",\"publisher\":{\"@id\":\"https:\/\/inbudgetalerts.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/inbudgetalerts.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/inbudgetalerts.com\/#organization\",\"name\":\"Fintech Advance\",\"url\":\"https:\/\/inbudgetalerts.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/inbudgetalerts.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/inbudgetalerts.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"contentUrl\":\"https:\/\/inbudgetalerts.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"width\":409,\"height\":70,\"caption\":\"Fintech Advance\"},\"image\":{\"@id\":\"https:\/\/inbudgetalerts.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/inbudgetalerts.com\/#\/schema\/person\/5fadb0c23fa3bfd2762b1a5dcce46da3\",\"name\":\"Press Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/inbudgetalerts.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/inbudgetalerts.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"contentUrl\":\"https:\/\/inbudgetalerts.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"caption\":\"Press Room\"},\"sameAs\":[\"https:\/\/inbudgetalerts.com\"],\"url\":\"https:\/\/inbudgetalerts.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN) | InBudgetAlerts","description":"This article was written byFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/inbudgetalerts.com\/?p=15182","og_locale":"en_US","og_type":"article","og_title":"Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN) | InBudgetAlerts","og_description":"This article was written byFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put","og_url":"https:\/\/inbudgetalerts.com\/?p=15182","og_site_name":"InBudgetAlerts","article_published_time":"2026-01-16T17:43:27+00:00","og_image":[{"width":1536,"height":1025,"url":"https:\/\/inbudgetalerts.com\/wp-content\/uploads\/2026\/01\/image_1306234498.jpg","type":"image\/jpeg"}],"author":"Press Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Press Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/inbudgetalerts.com\/?p=15182#article","isPartOf":{"@id":"https:\/\/inbudgetalerts.com\/?p=15182"},"author":{"name":"Press Room","@id":"https:\/\/inbudgetalerts.com\/#\/schema\/person\/5fadb0c23fa3bfd2762b1a5dcce46da3"},"headline":"Ocugen: Why I Don&#8217;t Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN)","datePublished":"2026-01-16T17:43:27+00:00","dateModified":"2026-01-16T17:43:27+00:00","mainEntityOfPage":{"@id":"https:\/\/inbudgetalerts.com\/?p=15182"},"wordCount":268,"commentCount":0,"publisher":{"@id":"https:\/\/inbudgetalerts.com\/#organization"},"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/inbudgetalerts.com\/?p=15182#respond"]}]},{"@type":"WebPage","@id":"https:\/\/inbudgetalerts.com\/?p=15182","url":"https:\/\/inbudgetalerts.com\/?p=15182","name":"Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN) | InBudgetAlerts","isPartOf":{"@id":"https:\/\/inbudgetalerts.com\/#website"},"datePublished":"2026-01-16T17:43:27+00:00","dateModified":"2026-01-16T17:43:27+00:00","description":"This article was written byFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put","breadcrumb":{"@id":"https:\/\/inbudgetalerts.com\/?p=15182#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/inbudgetalerts.com\/?p=15182"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/inbudgetalerts.com\/?p=15182#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/inbudgetalerts.com\/"},{"@type":"ListItem","position":2,"name":"Ocugen: Why I Don&#8217;t Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN)"}]},{"@type":"WebSite","@id":"https:\/\/inbudgetalerts.com\/#website","url":"https:\/\/inbudgetalerts.com\/","name":"Fintech Advance","description":"Latest Finance and Tech News and Updates","publisher":{"@id":"https:\/\/inbudgetalerts.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/inbudgetalerts.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/inbudgetalerts.com\/#organization","name":"Fintech Advance","url":"https:\/\/inbudgetalerts.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/inbudgetalerts.com\/#\/schema\/logo\/image\/","url":"https:\/\/inbudgetalerts.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","contentUrl":"https:\/\/inbudgetalerts.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","width":409,"height":70,"caption":"Fintech Advance"},"image":{"@id":"https:\/\/inbudgetalerts.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/inbudgetalerts.com\/#\/schema\/person\/5fadb0c23fa3bfd2762b1a5dcce46da3","name":"Press Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/inbudgetalerts.com\/#\/schema\/person\/image\/","url":"https:\/\/inbudgetalerts.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","contentUrl":"https:\/\/inbudgetalerts.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","caption":"Press Room"},"sameAs":["https:\/\/inbudgetalerts.com"],"url":"https:\/\/inbudgetalerts.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=\/wp\/v2\/posts\/15182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15182"}],"version-history":[{"count":1,"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=\/wp\/v2\/posts\/15182\/revisions"}],"predecessor-version":[{"id":15184,"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=\/wp\/v2\/posts\/15182\/revisions\/15184"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=\/wp\/v2\/media\/15183"}],"wp:attachment":[{"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inbudgetalerts.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}